Overview
CIC-rearranged sarcoma is a rare subtype of sarcoma characterized by chromosomal rearrangements involving the CIC gene, often leading to oncogenic fusion proteins. Selpercatinib, a selective TRK inhibitor, has shown efficacy in treating these malignancies 1.Diagnosis
Identification of CIC rearrangement through molecular testing (e.g., FISH, RT-PCR) 1.
Histopathological examination confirming sarcoma characteristics.
Clinical presentation may include specific metastatic patterns or organ involvement typical of TRK fusion-positive tumors.Management
First-line treatment: Selpercatinib is recommended, typically initiated at 160 mg twice daily 1.
Adjunctive management: Monitor for adverse events, particularly hepatic function abnormalities, hypersensitivity reactions, and neurological symptoms like dysphagia and hemiparesis 1.Special Populations
Weight considerations: Patients weighing less than 50 kg may have an increased risk of hypersensitivity reactions 1.
Geographical variations: Asian populations may experience more frequent hepatic function abnormalities at doses exceeding 160 mg 1.Key Recommendations
Initiate selpercatinib at 160 mg twice daily for CIC-rearranged sarcoma (Evidence: Moderate 1).
Closely monitor hepatic function, especially in Asian patients and those receiving doses above 160 mg (Evidence: Moderate 1).
Be vigilant for hypersensitivity reactions, particularly in patients weighing less than 50 kg (Evidence: Moderate 1).References
1 Qian J, Zhang S, Jiang C. Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database. BMC cancer 2024. link